Ascendis Pharma A-S

Yahoo Finance • 3 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which rep... Full story

Yahoo Finance • 3 months ago

RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc

Overview of Recent Transaction On September 12, 2024, RA Capital Management L.P., a prominent investment firm, executed a significant transaction by acquiring an additional 1,577,341 shares of Janux Therapeutics Inc (NASDAQ:JANX). This mo... Full story

Yahoo Finance • 3 months ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis Pharma –    TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) –    For children aged 5-11 years TransCon CNP demonstrated a change from baseline AGV superio... Full story

Yahoo Finance • 4 months ago

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Royalty Pharma plc Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept.... Full story

Yahoo Finance • 4 months ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 0... Full story

Yahoo Finance • 9 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 10 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript February 7, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day,... Full story

Yahoo Finance • 11 months ago

Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week

Passive investing in index funds can generate returns that roughly match the overall market. But you can do a lot better than that by buying good quality businesses for attractive prices. For example, the Ascendis Pharma A/S (NASDAQ:ASND)... Full story

Yahoo Finance • last year

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

Ascendis Pharma TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- As... Full story

Yahoo Finance • last year

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

–   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan –   Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up... Full story

Yahoo Finance • last year

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism

- YORVIPATH (developed as TransCon PTH) is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism - Ascendis plans its first EU launch of YORVIPATH in Germany in January 2024... Full story

Yahoo Finance • last year

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypo... Full story

Yahoo Finance • last year

Ascendis Pharma Reports Third Quarter 2023 Financial Results

European Commission decision for TransCon™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024 TransCon PTH NDA resubmission to FDA expected before mid-NovemberCompleted enrollment in the Ph... Full story

Yahoo Finance • last year

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-November 2023 COPENHAGEN, Denmark, Oct. 31, 2... Full story

Yahoo Finance • last year

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

— Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon IL-2 β⁄γ administer... Full story

Yahoo Finance • last year

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms — Bone turnov... Full story

Yahoo Finance • last year

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatmen... Full story

Yahoo Finance • last year

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of Tr... Full story

Yahoo Finance • last year

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly trea... Full story

Yahoo Finance • last year

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

-   Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A... Full story